Cardiovascular Medicine and Haematology articles for Italy

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 161

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
9 0.54
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.06
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension 0.04
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial. 0.06
Phenotyping Asthma and/or COPD Using 129Xe MRI and Comprehensive Physiologic Testing. 0.04
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study. 0.08
One-Year Change in Quantitative Computed Tomography Is Associated with Meaningful Outcomes in Fibrotic Lung Disease. 0.08
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.13
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.03
Select Airway Specialized Proresolving Mediators Are Associated with Recovery from Nonviral Chronic Obstructive Pulmonary Disease Exacerbations 0.03
1 0.06
A Frozen Elephant Trunk Technique to Reduce Circulatory Arrest Time in Hybrid Aortic Arch for Acute Aortic Dissection: Early and Midterm Outcomes in a Multicentric Cohort of 153 Patients. 0.06
2 0.42
Effects of different B-cell-depleting strategies on the lymphatic tissue 0.06
Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side effects and prevention strategies 0.36
1 1.00
Shining light in a heartbeat: Controlling cardiac bioelectricity with membrane-targeted photoswitches 1.00
5 2.32
Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database 0.24
Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study 0.05
<atl>Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with scpIL/scp ‐1 inhibitors</atl> 1.00
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations 0.03
Innate Lymphoid Cell phenotypic and functional alterations in systemic Juvenile Idiopathic Arthritis 1.00
4 0.68
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.05
Defective neutrophil clearance in JAK2 V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24 0.16
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA 0.44
Large B-cell lymphoma imprints dysfunctional immune phenotype that persists years after treatment 0.04
1 0.11
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis 0.11
1 0.47
<atl>Open surgery iversus/i branched endovascular repair of the aortic arch in residual dissections after type A surgical repair</atl> 0.47
6 1.97
Demographic and Physiological Differences Between Fibrotic and Nonfibrotic CT Subtypes of Sarcoidosis 0.05
Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey 0.07
Aspergillus fumigatus sensitization is associated with high-risk bronchiectasis 0.13
Acetazolamide plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment A Randomized Controlled Trial 0.82
Exercise Doppler Echocardiography of the right heart and pulmonary circulation in patients with cardiovascular risk factors: Observations from the RIGHT Heart International NETwork (RIGHT-NET) 0.85
Prediction pathway for severe asthma exacerbations: a Bayesian Network analysis 0.05
15 4.81
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.08
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.09
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.35
Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. 0.55
Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. 0.13
Prognostic Value of Exercise Right Ventricular-Pulmonary Arterial Coupling in Primary Mitral Regurgitation. 0.33
Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. 0.04
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. 0.05
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. 0.03
Clinical and Prognostic Significance of Anomalous Origin of a Coronary Artery in Adults. 1.00
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.23
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.24
Effect of Remote Ischemic Preconditioning on Myocardial Injury in Noncardiac Surgery: the PRINCE Randomized Clinical Trial. 0.66
Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study. 0.03
Genotype-Specific Outcomes of Desmosomal Cardiomyopathies. 1.00
2 2.00
Effects of High-Flow Nasal Cannula and Helmet Continuous Positive Airway Pressure in Acute Hypoxemic Respiratory Failure. 1.00
The Impact of High-Flow Nasal Cannula Therapy on Diaphragmatic Function Assessed by Ultrasound: A Pilot Clinical Study. 1.00
1 0.08
Sympathetic innervation maintains the murine quiescent skeletal muscle stem cell pool via perivascular-derived Angpt1 0.08
2 0.20
Metabolic Factors Modulating the Connection Between Diabetes and Pulmonary Alterations. 0.14
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. 0.06
26 6.18
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study 0.10
New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort 0.08
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.01
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.06
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model 0.04
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model 0.04
Laminopathies: natural history and risk prediction of heart failure 0.03
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study 0.05
Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades 0.09
Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score 0.76
The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk 0.36
Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial 0.11
Physiology vs angiography-guided percutaneous coronary intervention in transcatheter aortic valve implantation: the FAITAVI trial 1.00
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.06
Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction 0.01
Endotypes of angina with non-obstructive coronary arteries: a prospective multicentre study 0.47
Early outcomes of children with univentricular circulation undergoing Fontan surgery: the EuroFontan registry 0.52
Left ventricular geometry, brain architecture, and cognition: an observational study 0.10
Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study 1.00
Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study 0.13
Fulminant myocarditis: outcome predictors in an international cohort study 0.02
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.03
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis 0.11
Patient–prosthesis mismatch after aortic valve replacement: one size does not fit all 0.17
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.02
Mortality in male bodybuilding athletes 0.83
1 0.10
Epigenetic silencing of interleukin-10 by host-derived oxidized phospholipids supports a lethal inflammatory response to infections 0.10
3 0.70
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.00
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia 0.08
Respiratory Gas Shifts to Delay Asphyxiation in Critical Avalanche Burial 0.61
2 1.22
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma 0.64
Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark Zone 0.58
5 0.52
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.05
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. 0.20
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.07
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. 0.16
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. 0.05
5 2.88
Beat‐to‐beat variability of ventricular repolarization reveals sex‐specific instability and proarrhythmic risk 0.50
Mathematical model of the zebrafish ventricular cardiomyocyte action potential and calcium transient 0.33
Computational analysis to assess hemodynamic forces in descending thoracic aortic aneurysms 0.88
Elucidating the cellular determinants of the end‐systolic pressure‐volume relationship of the heart via computational modelling 1.00
Pathogenic TNNT1 variants are associated with aberrant thin filament compliance and myofibre hyper‐contractility 0.17
5 2.06
Complications following airway resections: Insights from a large contemporary multi-institutional cohort 0.25
Second cross-clamp in less invasive mitral valve repair for degenerative mitral regurgitation: Predictors and outcomes 0.37
Replacement of the superior vena cava by the bovine pericardium conduit: Sustained patency without long-term anticoagulation 1.00
Iatrogenic aortic dissection: Insights from the International Registry of Acute Aortic Dissection 0.06
Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: a substudy from the LAAOS III Trial 0.38
15 2.99
Potent P2Y12 Inhibitor Monotherapy versus DAPT after PCI in Patients With and Without STEMI: NEO-MINDSET Substudy 0.02
One-year outcomes of novel balloon-expandable versus contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial 0.07
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.06
Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction 0.12
Drug-coated balloon angioplasty versus upfront stenting for de novo CAD: 3-year follow-up of REC-CAGEFREE I trial 0.03
Computed Tomography Angiography or Standard Care After Left Main PCI? 0.90
Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial 0.92
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Exploratory Insights From the ODYSSEY-HCM Trial 0.05
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.08
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.04
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial 0.04
Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction 0.06
Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome An Optical Coherence Tomography Analysis 0.40
3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation Results From the SWISS-APERO Randomized Clinical Trial 0.17
Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patient 0.05
1 0.07
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.07
1 0.85
Reduced cyclin D3 expression in erythroid cells protects against malaria 0.85
5 2.04
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases 0.01
Extracellular activation of HCN4 by a subtype-specific nanobody 0.53
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.09
PI3Kγ signaling controls trafficking of CD8+ T cells between lymphoid and non-lymphoid organs and drives hypertension in a murine model 0.80
Imbalanced TGFβ signalling and autophagy drive erythroid priming of hematopoietic stem cells in β-thalassemia 0.61
5 0.20
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.04
Pulsed Field Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: 4-Year Outcomes in the Study 0.02
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.07
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.03
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial 0.04
1 0.10
Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials 0.10
1 0.04
Transcriptome fingerprinting of aberrant fibroblast activation unlocks effective therapeutics to tackle cardiac fibrosis 0.04
1 0.71
Functional correction of the untreatable CFTR 1717-1G>A mutation through mRNA- and sgRNA-optimized base editing 0.71
2 1.11
Sex related differences in efficacy and safety of antithrombotic therapy in patients with coronary artery disease: systematic review and meta-analysis 1.00
P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials 0.11
1 0.12
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.12
10 0.94
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study 0.01
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial 0.18
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.03
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.05
Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials 0.22
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.14
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.07
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.07
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials 0.09
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.07
1 0.08
Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis 0.08
17 2.29
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation 0.07
Angiography-Based Physiology to Guide Coronary Revascularization 0.24
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation 0.01
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia 0.08
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction 0.07
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 0.04
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction 0.04
Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction 0.08
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction 0.27
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 0.04
Multidomain Rehabilitation for Older Patients with Myocardial Infarction 1.00
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis 0.08
As-Needed Albuterol–Budesonide in Mild Asthma 0.05
Nerandomilast in Patients with Progressive Pulmonary Fibrosis 0.05
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis 0.06
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk 0.04
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype 0.06
3 0.13
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study 0.05
Acute breathlessness as a cause of hospitalisation in Malawi: a prospective, patient-centred study to evaluate causes and outcomes 0.04
129Xe-MRI ventilation and acinar abnormalities highlight the significance of spirometric dysanapsis: findings from the NOVELTY ADPro UK substudy 0.04

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.